Description
CAG Peptide: Benefits and Scientific Evidence
CAG (formerly AM833) is a long‑acting analog of amylin, a hormone co‑secreted with insulin by pancreatic β‑cells. It is engineered to resist fibril formation and bind amylin receptor subtypes with high affinity:contentReference[oaicite:0]{index=0}. By activating amylin receptors in the hindbrain and hypothalamus, cagrilintide reduces appetite and slows gastric emptying, leading to sustained decreases in energy intake:contentReference[oaicite:1]{index=1}.
Potential Advantages Over Other Therapies
Current pharmacologic options for obesity often have limited efficacy or are poorly tolerated. CAG’s ability to reduce weight with fewer gastrointestinal side effects may improve adherence compared with traditional GLP‑1 receptor agonists:contentReference[oaicite:11]{index=11}. Its extended half‑life allows for once‑weekly dosing, reducing injection burden:contentReference[oaicite:12]{index=12}. These features make cagrilintide—and especially the CagriSema combination—a promising alternative for people unable to tolerate higher‑dose GLP‑1 therapies or for those seeking non‑surgical weight‑loss strategies.
Key Research Articles
For further reading, refer to these PubMed‑indexed studies and reviews:
- CAG: A Long-Acting Amylin Analog for the Treatment of Obesity – summarizes amylin physiology and the rationale for combining cagrilintide with SemaG:contentReference[oaicite:13]{index=13}.
- Once-weekly cagrilintide for weight management – dose‑finding trial demonstrating dose‑dependent lypolosis.
- CAG lowers bodyweight through brain amylin receptors 1 and 3 – pre‑clinical mouse study showing receptor‑dependent lypolosis and reduced fat mass:contentReference[oaicite:14]{index=14}:contentReference[oaicite:15]{index=15}.
- Efficacy and safety of cagrilintide alone and in combination with SemaG (CagriSema) – systematic review and meta-analysis reporting >20 % weight reduction and improved tolerability:contentReference[oaicite:16]{index=16}:contentReference[oaicite:17]{index=17}.
Disclaimer: CAG is an investigational peptide. The information presented here is for educational purposes only and not an endorsement for self‑administration. Clinical use requires regulatory approval and physician supervision.
PLEASE NOTE THAT ALL PRODUCTS FEATURED HERE ARE INTENDED EXCLUSIVELY FOR RESEARCH AND DEVELOPMENT PURPOSES. THEY ARE NOT DESIGNED FOR ANY FORM OF HUMAN CONSUMPTION. THESE PRODUCTS HAVE NOT UNDERGONE EVALUATION BY THE U.S. FOOD AND DRUG ADMINISTRATION.
